ten23 health becomes first sterile product CDMO to earn B Corp certification

ten23 health, the human-centric, sustainable contract development and manufacturing organization (CDMO), and strategic partner for the pharmaceutical industry, is proud to announce its official certification as a B Corporation (B Corp). ten23 health is the first biotech and sterile drug product CDMO in the pharmaceutical sector to achieve B Corp certification, which recognizes its dedication to meeting rigorous standards of social and environmental performance, accountability, and transparency.

This prestigious B Corp certification is a testament to a company that voluntarily meets the highest standards in Environmental, Social and Corporate Governance (ESG). These standards were developed independently and cover a company´s impact in key areas including governance, workers, community, environment and customers. The B Corp standards are intentionally set high and are intended to provide recognition for companies leading the sustainable transition of our economy.

“Companies like ours that operate in the pharmaceutical sector are used to the demands of a tightly regulated environment,” said Hanns-Christian Mahler, CEO of ten23 health. “We believe that it is not enough simply to state ethical and environmental aspirations, but it is also critical to voluntarily achieve ambitious and recognized standards like the B Corp certification. After all, our marketplaces are reliant on top ethical standards to protect the environment, professionals and patients. It is our mission to leave a heart-print related to sustainability for our customers, other CDMOs and our employees alike, and I am proud and happy to see our Fairstainability agenda at ten23 health being validated by becoming a B Corp,” added Mahler.

"We embarked on our B Corp journey from Day 1 onwards as a start-up, with the firm ambition of creating lasting positive impacts, leading to our B Corp “pending” status with our submission for certification as early in 2022. After two years of dedicated efforts, we are proud to earn this certification, with unique recognition in the Pharmaceutical and CDMO industry,” commented Cedric Montagne, Sustainability Expert at ten23 health. “At ten23 health, our goal is to surpass benchmarks, continuously raising the bar for higher standards and improvement beyond regulatory requirements. This certification is a validation of that commitment,” said Alissa Monk, Fairstainability Co-Officer at ten23 health. “We are proud to have received the certification and hope to inspire other companies and CDMOs to do the same, putting fairness and sustainability as a top priority,’’ concluded Carole Schanté, Fairstainability Co-Officer at ten23 health.

As a newly certified B Corp, ten23 health joins a global movement of companies using “business as a force for good”. The certification highlights the company’s commitment to fostering a positive impact on its employees, communities, and the environment while maintaining high standards of transparency and ethics in its business practices.